Evaluation of Effect of CryoBalloon Focal Ablation System on Human Esophageal Barrett's Epithelium
This study is currently recruiting participants.
Verified May 2013 by C2 Therapeutics, Inc.
Sponsor:
C2 Therapeutics, Inc.
Information provided by (Responsible Party):
C2 Therapeutics, Inc.
ClinicalTrials.gov Identifier:
NCT01633411
First received: June 28, 2012
Last updated: May 1, 2013
Last verified: May 2013
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
This is a feasibility study without a primary study hypothesis or statistical comparison.
| Condition | Intervention | Phase |
|---|---|---|
|
Barrett's Esophagus |
Device: Cryoballoon Focal Ablation System - 6 seconds Device: Cryoballoon Focal Ablation System - 8 seconds |
Phase 1 |
| Study Type: | Observational |
| Study Design: | Observational Model: Cohort Time Perspective: Prospective |
| Official Title: | Evaluation of Effect of CryoBalloon Focal Ablation System on Human Esophageal Barrett's Epithelium |
Resource links provided by NLM:
Further study details as provided by C2 Therapeutics, Inc.:
Primary Outcome Measures:
- Esophageal Stricture [ Time Frame: 6 to 8 Weeks ] [ Designated as safety issue: Yes ]Stricture formation is defined as none, mild (non-circumferential stenosis allowing easy passage of diagnostic endoscope), moderate (circular stenosis allowing passage of diagnostic endoscope), and severe (any stenosis preventing the passage of a diagnostic scope).
Secondary Outcome Measures:
- Post-procedure pain relative [ Time Frame: Pre-ablation,12 hrs post ablation, 2 days (+ or - 1 day) ] [ Designated as safety issue: Yes ]A secondary objective of the study is to determine patient comfort post-procedure. Pain scores are measured on a numerical pain intensity scale (0 to 10). Patients is asked to score pain level in the treatment area and swallowing.
- Presence of Residual Barrett's Esophagus [ Time Frame: 6 to 8 weeks ] [ Designated as safety issue: No ]
Esophageal tissue subjected to ablation via the CryoBalloon Focal Ablation System will be submitted for histological evaluation. The evaluation will include:
- detailed description of the presence of Barrett's Esophagus and/or squamous mucosa.
- estimate of percentage of residual Barrett's in each sample
- the detailed description of any residual injury at all levels within the sample.
| Estimated Enrollment: | 40 |
| Study Start Date: | November 2012 |
| Estimated Study Completion Date: | December 2013 |
| Estimated Primary Completion Date: | September 2013 (Final data collection date for primary outcome measure) |
| Groups/Cohorts | Assigned Interventions |
|---|---|
|
Cohort A
Subjects in Cohort A will receive 6 seconds of Cryoballoon Focal Ablation to esophageal tissue.
|
Device: Cryoballoon Focal Ablation System - 6 seconds
Ablation of Barrett's Esophagus using a Focal Cryoballoon ablation catheter. The System is a Class II device "intended to be used as a cryosurgical tool for the destruction of unwanted tissue in the field of general surgery, specifically for endoscopic applications."
|
|
Cohort B
Subjects in Cohort B will receive 8 seconds of Cryoballoon Focal Ablation to esophageal tissue.
|
Device: Cryoballoon Focal Ablation System - 8 seconds
Ablation of Barrett's Esophagus using a Focal Cryoballoon ablation catheter. The System is a Class II device "intended to be used as a cryosurgical tool for the destruction of unwanted tissue in the field of general surgery, specifically for endoscopic applications."
|
Detailed Description:
The purpose of this study is to assess the safety, feasibility, and performance of the C2 Focal Cryoablation Device in patients with Barrett's Esophagus (BE). At 6 to 8 weeks, the patient will receive a follow-endoscopy to assess stricture formation along with biopsy samples taken.
Post-operative pain will be noted. Additionally, biopsy samples will be evaluated for the presence of residual Barrett's Esophagus. Through evaluation of the histological results, treatment parameters for the ablation of human esophageal epithelium will be better understood.
Evaluations include, but are not limited to the following:
- Deployment ease/scope compatibility.
- Device malfunctions.
- Time of catheter deployment.
- Adverse events.
- Stricture formation at 6 to 8 weeks.
- Patient Pain.
- Histological evaluation of treatment zone at 6 to 8 weeks for presence of residual Barrett's Esophagus.
Eligibility| Ages Eligible for Study: | 18 Years to 80 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Non-Probability Sample |
Study Population
Patients with Barrett's esophagus with or without dysplasia
Criteria
Inclusion Criteria:
- Patients scheduled for ablation, EMR, and/or surveillance for BE (with or without dysplasia). Patient is 18 to 80 years of age at the time of consent (inclusive).
- Patient has provided written Informed Consent (IC) using an Informed Consent Form (ICF) that has been approved by the Institution's reviewing IRB/EC.
- Patient is willing and able to comply with all Clinical Investigation Plan (CIP) requirements.
- Patient is deemed operable per standard institutional criteria.
Exclusion Criteria:
- Patient with endoscopically active inflammation in the treatment zone
- Esophageal stenosis preventing advancement of a therapeutic endoscope and/or within 4 cm of treatment zone.
- Patient has a known history of unresolved drug or alcohol dependency that would limit ability to comprehend or follow instructions related to informed consent, post treatment instructions or follow-up guidelines.
- Patient refuses or is unable to provide written informed consent.
- Patients that are pregnant.
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01633411
Contacts
| Contact: Peter Garcia-Meza, BS | 650-521-5304 | peter@c2therapeutics.com |
Locations
| United States, California | |
| University of Southern California | Recruiting |
| Los Angeles, California, United States, 90033 | |
| Contact: Christina Greene, MD Christina.Greene@med.usc.edu | |
| Principal Investigator: Steve DeMeester, MD | |
| United States, Maryland | |
| John Hopkins | Recruiting |
| Baltimore, Maryland, United States, 21205 | |
| Contact: Hilary Cosby, RN hcosby1@jhmi.edu | |
| Principal Investigator: Mimi Canto, MD | |
| United States, New York | |
| Columbia Medical Center | Recruiting |
| New York, New York, United States, 10032 | |
| Sub-Investigator: Julian Abrams, MD | |
| Principal Investigator: Charles Lightdale, MD | |
| University of Rochester | Recruiting |
| Rochester, New York, United States, 14642 | |
| Contact: Michal Lada, MD michal_lada@urms.rochester.edu | |
| Principal Investigator: Jeff Peters, MD | |
| United States, Pennsylvania | |
| Allegheny-Singer Research Institute | Recruiting |
| Pittsburgh, Pennsylvania, United States, 15212 | |
| Principal Investigator: Blair Jobe, M | |
| Sub-Investigator: Toshitaka Hoppo, MD | |
| Netherlands | |
| Academic Medical Center Amsterdam | Recruiting |
| Amsterdam, Netherlands | |
| Contact: Dirk Schölvinck, pHD d.w.scholvinck@amc.uva.nl | |
| Principal Investigator: Bas L Weusten, MD | |
| Sub-Investigator: Jacques Bergman, MD | |
| St. Antonius Hospital | Recruiting |
| Nieuwegein, Netherlands | |
| Contact: Dirk Schölvinck, MD d.w.scholvinck@amc.uva.nl | |
| Principal Investigator: Bas Weusten, MD, PhD | |
| Universitair Medisch Centrum Utrecht | Recruiting |
| Utrecht, Netherlands | |
| Contact: Christine Kestens c.kestens@umcutrecht.nl | |
| Principal Investigator: Peter Siersema, MD, PhD | |
| Sub-Investigator: Frank Vleggaar, MD, PhD | |
Sponsors and Collaborators
C2 Therapeutics, Inc.
Investigators
| Principal Investigator: | Bas L Weusten, MD, pHD | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) |
More Information
Additional Information:
Publications:
| Responsible Party: | C2 Therapeutics, Inc. |
| ClinicalTrials.gov Identifier: | NCT01633411 History of Changes |
| Other Study ID Numbers: | CP-0003.A |
| Study First Received: | June 28, 2012 |
| Last Updated: | May 1, 2013 |
| Health Authority: | United States: Institutional Review Board Netherlands: Medical Ethics Review Committee (METC) |
Additional relevant MeSH terms:
|
Barrett Esophagus Digestive System Abnormalities Digestive System Diseases Esophageal Diseases Gastrointestinal Diseases |
ClinicalTrials.gov processed this record on May 19, 2013